Patient P-01616

Synthetic patientNBL-101 · Day 119 · 25–34 · F · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

83%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 59 GI symptom burden −33% vs expected — GI Support Protocol GI-04
Day 65 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Toxicity-17
GI instability+15
Inflammatory activity+7
Nutritional resilience-4

What helped?

GI Support Protocol GI-04Day 50
Result: symptom burden −33%

LIFE OS recommendation

Dietary Support Protocol NP-02

65%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.3 h, below personal baseline
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 84 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.7 · butyrate capacity 45/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 5.3 h
Steps: 7,472
Resting HR: 83 bpm

Daily log: GI score 59, nutritional resilience 43, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01307	53%	S14	GI-04	improved	43
P-01356	50%	S14	GI-04	improved	42
P-01458	49%	S14	GI-04	improved	44
P-01473	49%	S14	GI-04	improved	51
P-01505	48%	S14	NP-02	improved	41
P-01539	47%	S14	GI-04	improved	43
P-01570	47%	S14	SC-12	improved	46
P-01365	46%	S14	SC-12	improved	49
P-01486	46%	S18	GI-04	improved	47
P-01556	46%	S14	GI-04	improved	44
P-01603	46%	S14	GI-04	improved	40
P-01339	44%	S14	GI-04	improved	54